Jincheng Tongda & Neal‘s wide-ranging practice encompasses IP disputes, M&A and compliance matters, with clients ranging from pharmaceutical and healthcare enterprises to emerging biotechnology firms. Yingzhi Feng is well-versed in regulations, policy environment and local law enforcement relating to capital markets and private equity funds. An Huan frequently advises health administrative agencies, medical and pharmaceutical companies on medical dispute resolution, risk prevention and control system matters.
Legal 500 Editorial commentary
Key clients
- China Resources Pharmaceutical Holdings Company Limited
- China Resources Sanjiu Medical & Pharmaceutical Co.,Ltd
- Creative Biosciences
- Zhengye Biotechnology Holding Limited
- Zhejiang Starry Pharmaceutical Co.,Ltd.
- Shandong Hongjitang Pharmaceutical Group Co.,Ltd.
Work highlights
Assists China Resources Pharmaceutical Holdings in acquiring Sichuan Nanguo Biotechnology Co., Ltd.
Represented CR Sanjiu in a trademark infringement dispute – “999” and “Sanjiu” recognised as well-known trademarks by the Court.
Dispute over loans by pharmaceutical investment M&A funds on behalf of Shanghai Guopao to acquire an equity investment fund partnership enterprise.
Other key lawyers
Yingzhi Feng; Huan An